Dallas Biotech Lupagen Partners With Global Transfusion Leader to Advance Bedside Cell and Gene Therapy

The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.

Dallas-based Lupagen Inc., a pioneer in cell and gene therapy delivery, has announced a new development and supply agreement with Fresenius Kabi, a global leader in injectable medicines, infusion technology, and clinical nutrition.

The deal aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, according to a news release. Lupagen’s system focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.

Under the agreement, Fresenius Kabi will provide expertise from its transfusion medicine unit to optimize Lupagen’s platform for delivering cell and gene therapy treatments at a patient’s bedside.

With a U.S. headquarters in Illinois and global headquarters in Germany, Fresenius Kabi has an international presence.

Lupagen Co-founder and CEO Nipon Das says the collaboration with the global leader in blood and cell technologies “accelerates deployment of our solution to patients who need these treatments the most.”

Nipon Das, CEO of Lupagen. [Photo: Lupagen]

Das says the biotech wants to make cell and gene therapy as common and accessible as standard blood transfusion or dialysis procedures.

Founded in 2017, the biotech is headquartered in Dallas at Cypress Waters with a development site in Chicago. Lupagen is developing technologies to deliver cell and gene therapies, including CAR-T cancer treatments, gene editing, and immunotherapies. The therapies are created using a patient’s own cells processed outside the body.

“The biggest challenges that the cell and gene therapy community are facing are cost and complexity of production,” Das told Dallas Innovates last year. The company is tackling both.

Working internally and in partnership with other biopharma companies, Lupagen also develops nanoparticle-based gene therapies that can be delivered by its point-of-care system.

Collaborating for cell and gene therapy bedside access

Cell and gene therapies have shown promise for many conditions, including cancers and hematologic, autoimmune, and rare diseases.

Together, Lupagen and Fresenius Kabi aim to overcome key barriers around manufacturing, logistics, and costs that have limited patient access to those therapies. Their “to the bedside” approach could help open cutting-edge treatments to local hospitals and patients worldwide.

“Cell and gene therapies have helped treat or cure some of society’s most complex and challenging diseases, but more needs to be done to bring the delivery of these technologies closer to patients,” Fresenius Kabi’s Bryan Blickhan said in a statement.

Blickhan, the company’s senior vice president of R&D and device production, transfusion medicine, and cell therapies, called the agreement with Lupagen a “great step” toward more affordable and scalable therapies for people.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

  • "There are over 10,000 rare diseases that affect millions of people worldwide, and most of them are genetic," notes UT Southwestern's Steven Gray (above, with Susan Iannaccone, M.D.). Testing on a total of eight genetic diseases has been approved for funding by the Bespoke Gene Therapy Consortium and other organizations.

  • Dallas-based Taysha Gene Therapies is starting a new chapter in its fight to tackle devastating neurological conditions with changes in its top executive leadership. Late Friday, the publicly traded biotech announced that Sean P. Nolan, the current chair of the board of directors and an experienced biopharmaceutical industry leader, is the company's new CEO. Nolan succeeds RA Session II, who has resigned from the post. Session will continue to serve on the company's board of directors, Taysha said in a news release. In addition, Sukumar (Suku) Nagendran M.D., a seasoned physician, pharmaceutical developer, and biotech executive was named president and…

  • UT Southwestern researchers have used gene editing technology to develop what could be a breakthrough for dilated cardiomyopathy, a heart condition that affects one in 250 people worldwide. “The pace of this field is really breathtaking,” said Eric Olson, Ph.D., who co-led the study. “I expect that if this moves forward into patients, we’re not talking within decades—we’re talking within years.”​ 

  • Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.

  • Irving-based Biote Corporation, a preventive healthcare solutions provider that delivers personalized hormone therapy, has appointed John Denne as general manager of its men's health division. The move is aimed at expanding the company's presence in the growing market for male hormone replacement therapy. Biote, which was founded in 2012, went public on Nasdaq in May 2022 through a SPAC deal. Denne, a healthcare industry veteran with more than 30 years of experience in sales, business development, strategic marketing, and management, is expected to spearhead Biote's sales initiatives to fulfill a largely unmet medical need for millions of men seeking safe…